NASDAQ:SSKN

Strata Skin Sciences Stock News

Healthcare > Medical - Devices

Buy SSKN

*Your capital is at risk

$0.133

+0 (+0%)

At Close: Jun 03, 2026

STRATA Skin Sciences Announces CMS Recognition of Expanded CPT Codes for Inflammatory and Autoimmune Dermatologic Conditions with Company Anticipating Wider Excimer Adoption Ahead Of 2027 CPT Expansion

08:00am, Thursday, 06'th Nov 2025

Higher reimbursement, regulatory clarity, and acknowledgment of future indication expansion expected to reinforce physician confidence and support continued expansion Higher reimbursement, regulatory

STRATA Skin Sciences to Report Third Quarter 2025 Financial Results on November 13, 2025 and Provide Corporate Update

08:00am, Wednesday, 05'th Nov 2025

HORSHAM, Penn., Nov. 05, 2025 (GLOBE NEWSWIRE) -- STRATA Skin Sciences, Inc. (“STRATA” or the “Company”) (NASDAQ: SSKN), a medical technology company dedicated to developing, commercializing,

Excimer Laser Demonstrates Promising Results in Treating Rare Variant of Cutaneous Lymphoma, Mycosis Fungoides

08:15am, Tuesday, 14'th Oct 2025

First English-language case study shows resolution of lesions with 308-nm Excimer laser in rare mycosis fungoides (MF) subtype, poikilodermatous mycosis fungiodes (pMF), underscoring the Company's XTR

Marking Eczema Awareness Month – Clinical Research Validates Strata Skin Sciences' XTRAC® Excimer Laser as a Breakthrough Therapy for Localized Atopic Dermatitis

10:50am, Friday, 03'rd Oct 2025

HORSHAM, Pa., Oct. 03, 2025 (GLOBE NEWSWIRE) -- In recognition of Eczema Awareness Month, STRATA Skin Sciences, Inc. (“STRATA” or the “Company”) (NASDAQ: SSKN), a medical technology company de

STRATA Skin Sciences Receives Continued Validation for its Personalized Approach with New Published Study Highlighting XTRAC® Excimer Laser Treatment Combined with a Topical Drug in Psoriasis

08:15am, Tuesday, 30'th Sep 2025

HORSHAM, Pa., Sept. 30, 2025 (GLOBE NEWSWIRE) -- STRATA Skin Sciences, Inc. (“STRATA” or the “Company”) (NASDAQ: SSKN), a medical technology company dedicated to developing, commercializing, a

New Peer Reviewed Publication of Combination Therapy in Vitiligo with STRATA Skin Sciences' Excimer Laser and JAK Inhibitors Demonstrated Superior Safety and Unprecedented Response Rates, Providing Continued Validation of Personalized Medicine Approach

08:15am, Monday, 22'nd Sep 2025

Investigator-initiated randomized controlled combination trial published in the International Journal of Dermatology confirms its superiority to monotherapy, fueling continued market growth and expand

STRATA Skin Sciences Announces Closing of $2.42 Million Registered Direct Offering

04:05pm, Thursday, 04'th Sep 2025

HORSHAM, Pa., Sept. 04, 2025 (GLOBE NEWSWIRE) -- STRATA Skin Sciences, Inc. (“STRATA” or the “Company”) (Nasdaq: SSKN), a medical technology company dedicated to developing, commercializing, a

STRATA Skin Sciences' Elevate 360 Consulting Offering Drives Growth in Partner Clinic Operations and Fuels New Partnership Agreements

08:15am, Thursday, 04'th Sep 2025

Consulting program optimizes partner clinic businesses with implementation of best practices initiatives, including marketing, reimbursement, and patient retention Consulting program optimizes partner

STRATA Skin Sciences, Inc. (SSKN) Q2 2025 Earnings Call Transcript

09:14pm, Wednesday, 13'th Aug 2025

STRATA Skin Sciences, Inc. (NASDAQ:SSKN ) Q2 2025 Earnings Conference Call August 13, 2025 4:30 PM ET Company Participants Dolev Rafaeli - President, CEO & Vice-Chairman John Gillings - Principal Fina

STRATA Skin Sciences Moves to Accelerate Medicare and Private Payer Coverage from Expanded CPT Code Expansion, Tripling Addressable Market to 30M+ Patients

08:15am, Thursday, 07'th Aug 2025

Peer-reviewed publications continue to validate Excimer Laser efficacy in vitiligo and treatment STRATA updates status of non-Excimer laser false advertising litigation HORSHAM, Pa., Aug. 07, 2025 (G

Top Fintech Company

featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by